The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1416
May 13, 2013
View Complete Issue         Table of Contents 2019 
Pasireotide (Signifor) for Cushing's Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Pasireotide (Signifor) for Cushing's Disease
May 13, 2013 (Issue: 1416)
The FDA has approved the somatostatin analog pasireotide diaspartate (Signifor – Novartis) for treatment of adults with Cushing's disease (cortisol excess caused by an ACTH-secreting pituitary tumor) who are not candidates for pituitary surgery...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Pasireotide (Signifor) for Cushing's Disease
Article code: 1416b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.